Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for advanced thyroid cancer: personalized drug cocktails tested

NCT ID NCT07485569

Disease control Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 03, 2026 · Updated 5 times

Summary

This early-phase trial tests whether giving advanced thyroid cancer patients a personalized mix of already-approved drugs, chosen based on their tumor's genetic profile, is feasible and safe. Ten patients with no other treatment options will receive individualized drug combinations. The goal is to see if this approach can control tumor growth or stop it from worsening.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
approved drugs (personalized combination)
What this could lead to
If successful, this could show that personalized drug repurposing is feasible and safe, potentially offering a new treatment path for advanced thyroid cancer patients.
What could go wrong
This is a very early, small pilot trial with only 10 participants. It may not show clear benefit, and the personalized approach may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with locally advanced or metastatic TC (such as ATC, PDTC, and RAI refractory DTC progressive under treatment with multikinase inhibitors) for whom no approved conventional treatments are available. * Prior anticancer treatment-related toxicities resolved to Grade ≤1 (CTCAE v5.0). * Measurable disease per RECIST 1.1 * ECOG performance status ≤ 2 * Negative pregnancy test within 7 days prior to starting the study in women of childbearing potential and adequate use of contraception. Exclusion Criteria: * Inability to provide informed consent * Inability to obtain a (new) biopsy for molecular profiling * Pregnancy or breastfeeding. * Other active malignancies requiring therapy. * Neutropenia (ANC \< 1.5 × 10⁹/L). * Severe uncontrolled medical conditions (renal, cardiac, liver, respiratory).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anaplastic thyroid cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

differentiated thyroid carcinoma poorly differentiated thyroid gland carcinoma thyroid cancer thyroid gland undifferentiated (anaplastic) carcinoma Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anaplastic thyroid cancer Differentiated thyroid cancer Poorly differentiated thyroid carcinoma Thyroid cancer stage IV

Contacts and locations

Locations

  • Radboudumc

    Nijmegen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.